Genentech, manufacturers of bevacizumab (Avastin), recently discontinued two clinical trials combining their drug with Pfizer’s sunitinib malate (Sutent) after several cases of microangiopathic... [Read More]

The European Medicines Agency (EMEA) has recommended updating the product information for epoetin-containing medicines with a new warning for their use in cancer patients being treated in Europe. The... [Read More]

The Oncology Drugs Advisory Committee of the Food and Drug Administration (FDA) will discuss the cumulative data, including recent study results, on the risks of erythropoiesis-stimulating agents... [Read More]

An international working party recently developed guidelines for evaluation and treatment of anemia and iron deficiency in inflammatory bowel disease patients that should serve practicing... [Read More]

A recent clinical trial and review in the New England Journal of Medicine concluded treating anemia with erythropoietin did not significantly reduce blood transfusion rates or incidence of death... [Read More]

Recent information and research about anemia management of chronic kidney disease (CKD) has prompted the National Kidney Foundation to revise their Clinical Practice Guidelines on Anemia and CKD. The... [Read More]

A federal advisory committee met September 11, 2007 to address restrictions for anemia drugs used to treat patients with kidney disease. The panel advising the Food and Drug Administration (FDA)... [Read More]

A non-binding resolution from the U.S. Senate called for the Centers for Medicare & Medicaid Services (CMS) to immediately reevaluate its anemia drug reimbursement policy. The September 4th... [Read More]

The American Society of Clinical Oncology (ASCO) has expressed concern over revised reimbursement policy for anemia drugs, repeatedly asking the Centers for Medicare & Medicaid Services (CMS) to... [Read More]

Two decades after publishing his groundbreaking clinical trial with a synthetic form of erythropoietin, nephrologist Dr. Joseph W. Eschbach died at his home in Bellevue, Washington on September 7th... [Read More]

The Centers for Medicare & Medicaid Services released updated rules for its coverage of anemia drugs used to treat cancer patients. The final decision imposed fewer restrictions than initially... [Read More]

In March, the FDA mandated stronger labeling for anemia drugs (erythropoietin) concerning their use for cancer patients. Recently, the FDA advisory committee has taken further steps, calling for more... [Read More]